针对RAS突变特异性信号传递动态在对paralog和状态选择性RAS抑制剂的反应中
bioRxiv : the preprint server for biology
|April 1, 2025
概括
信号抑制指数 (SII) 在RAS向抑制剂之间有显著差异,大多数KRAS突变瘤对单个药物不敏感. 根据特定的RAS突变和细胞环境定制疗法对于改善结果至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 高治疗指数 (TI) 对于有效的癌症疗法至关重要,平衡瘤细胞的向抑制,对正常细胞的影响最小.
- 向RAS的抑制剂,包括突变特异性,相对选择性和状态选择性类型,已经推进了癌症治疗.
- 信号抑制指数 (SII),代表RAS突变 (RAS(MUT)) 和正常细胞之间的差异性抑制,对于这些抑制剂来说定义不佳.
研究的目的:
- 在各种RAS突变 (RAS(MUT)) 和RAS野生型 (RAS(WT)) 模型中评估状态和对应选择性RAS抑制剂的SII.
- 定义通过各种RAS向策略实现的瘤原体信号的差异抑制.
- 通过了解SII变异性,为RAS向疗法的设计和临床应用提供信息.
主要方法:
- 在各种RAS (MUT) 和RAS (WT) 模型中评估panRAS-GEF (OFF),panKRAS (OFF) 和panRAS (ON) 抑制剂的SII.
- 在突变细胞与野生类型细胞中对MAPK抑制的评估.
- 在具有特定RAS突变 (例如KRAS(G12X),KRAS(G13D,RAS(Q61X)) 和遗传背景 (例如NF1损失) 的模型中分析抑制剂疗效.
主要成果:
- 泛RAS-GEF (OFF) 抑制剂表现为中性或负性SII,在RAS (MUT) 细胞与RAS (WT) 细胞中具有相似或减少的MAPK抑制.
- 潘克拉斯-GEF (OFF) 抑制剂的SII比潘克拉斯-GEF (OFF) 抑制剂高,表明瘤与正常细胞的选择性更好.
- 泛RAS(ON) 抑制剂表现出更广泛的活性,但相对狭窄的SII.
- RAS(Q61X) 模型对SHP2+MEK抑制剂组合具有耐药性,这是由于NRAS的重新激活和SHP2结合的受损.
- 所有测试的RAS抑制剂 (突变特异性,状态特异性和异位选择性) 都在相同的RAS (MUT) 模型子集中活跃,大多数RAS (MUT) 细胞系对所有细胞系都不敏感.
结论:
- 在RAS向抑制剂中存在显著的SII变异性,这取决于特定的RAS驱动突变和细胞环境.
- 泛RAS-GEF (OFF) 抑制剂通常表现出最低的SII.
- 大多数RAS突变瘤可能对任何单一的RAS向抑制剂不敏感.
- 将SII考虑因素纳入RAS向疗法的开发和临床应用中,对于改善治疗结果至关重要.
更多相关视频
相关概念视频
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Small GTPases - Ras and Rho
3.8K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.8K
MAPK Signaling Cascades
5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The JAK-STAT Signaling Pathway
8.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.5K


